| Abstrakt: |
A recent study conducted by researchers at the University of Bari in Italy explores the potential of using dopamine and citicoline-co-loaded solid lipid nanoparticles (SLNs) as nanomedicines for the treatment of Parkinson's disease (PD) through intranasal administration. The researchers designed and characterized these nanosystems, evaluating their particle size, surface charge, encapsulation efficiency, morphology, and physical stability. In vitro release tests in simulated nasal fluid (SNF) showed sustained release of dopamine. The study also demonstrated the high cytocompatibility of the SLNs with human nasal RPMI 2650 and neuronal SH-SY5Y cells, as well as their potential protective effect against oxidative cellular damage. Overall, the findings suggest that these SLNs could be a promising formulation for the treatment of PD. [Extracted from the article] |
